CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer

Cetuximab (C225), an anti-Epidermal Growth Factor receptor (EGFR) monoclonal antibody, has been widely used as a routine treatment for patients with metastatic colorectal cancer (mCRC); However, many patients who initially respond to cetuximab acquire resistance. The purpose of this study was to cha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cancer Res
Main Authors: Gao, Lingling, Xu, Jietian, He, Guodong, Huang, Jing, Xu, Weiyue, Qin, Jie, Zheng, Peng, Ji, Meiling, Chang, Wenju, Ren, Li, Wei, Yi, Xu, Jianmin, Liang, Chunmin
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895444/
https://ncbi.nlm.nih.gov/pubmed/31815051
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados